中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

127 records (took 0.021 seconds)

    MUSCARINIC RECEPTOR ANTAGONISTS
    31.
    发明申请
    MUSCARINIC RECEPTOR ANTAGONISTS 审中-公开
    肌肉受体拮抗剂

    公开(公告)号：US20090326004A1

    公开(公告)日：2009-12-31

    申请号：US12473481

    申请日：2009-05-28

    Applicant: Naresh KUMAR ,  Jitendra A. SATTIGERI ,  Shelly AERON ,  Malvika GARG ,  Abhijit RAY ,  Suman GUPTA ,  Shivani MALHOTRA ,  Raj Kumar SHIRUMALLA

    Inventor： Naresh KUMAR ,  Jitendra A. SATTIGERI ,  Shelly AERON ,  Malvika GARG ,  Abhijit RAY ,  Suman GUPTA ,  Shivani MALHOTRA ,  Raj Kumar SHIRUMALLA

    IPC: A61K31/439 ,  C07D453/02 ,  A61P1/06

    CPC classification number: C07D453/02

    Abstract: The present invention relates generally to muscarinic receptor antagonist, which are useful, among other uses, for the treatment of various diseases of the respiratory, urinary and gastrointestinal systems mediated through muscarinic receptors. The invention also relates to the process for the preparation of disclosed compounds, pharmaceutical compositions containing the disclosed compounds and the method for treating diseases mediated through muscarinic receptors. Also provided herein are pharmaceutical composition comprising one or more muscarinic receptor antagonists and at least one other active ingredients include, but are not limited to, corticosteroids, beta agonists, leukotriene antagonists, 5-lipoxygenase inhibitors, anti-histamines, antitussives, dopamine receptor antagonists, chemokine inhibitors, p38 MAP Kinase inhibitors, and PDE-IV inhibitors.

    Abstract translation: 本发明一般涉及毒蕈碱受体拮抗剂，其可用于治疗通过毒蕈碱受体介导的呼吸，泌尿和胃肠系统的各种疾病，以及其它用途。 本发明还涉及制备所公开的化合物的方法，含有所公开的化合物的药物组合物和用于治疗通过毒蕈碱受体介导的疾病的方法。 本文还提供包含一种或多种毒蕈碱受体拮抗剂的药物组合物，并且至少一种其它活性成分包括但不限于皮质类固醇，β激动剂，白细胞三烯拮抗剂，5-脂氧合酶抑制剂，抗组胺药，止咳药，多巴胺受体拮抗剂 ，趋化因子抑制剂，p38 MAP激酶抑制剂和PDE-IV抑制剂。

    SYSTEM AND METHOD FOR BILLING SYSTEM INTERFACE FAILOVER RESOLUTION
    32.
    发明申请
    SYSTEM AND METHOD FOR BILLING SYSTEM INTERFACE FAILOVER RESOLUTION 有权
    用于计费系统界面故障分解的系统和方法

    公开(公告)号：US20090319596A1

    公开(公告)日：2009-12-24

    申请号：US12141203

    申请日：2008-06-18

    Applicant: Naresh Kumar ,  Robert Perry

    Inventor： Naresh Kumar ,  Robert Perry

    IPC: G06F15/16

    CPC classification number: H04L12/14 ,  G06F11/2033 ,  G06F11/2038 ,  G06F11/2041 ,  H04L12/1403 ,  H04L69/40 ,  H04M15/70 ,  H04M15/74 ,  H04M2215/70 ,  H04M2215/709

    Abstract: A determination is made whether a first application server of a group of N application servers, N being at least two, is a coordinator of the group. Responsive to determining that the first application server is the coordinator of the group, a connection to a billing system is established, via a terminal server, by the first application server. A determination is made whether a second application server of the group of N application servers is the coordinator of the group. Responsive to determining that the second application server is not the coordinator of the group, a periodic check is made whether the second application server of the group of N application servers is the coordinator of the group. The second application server may later be determined to be the coordinator of the group, when the first server experiences difficulty. Once it is determined that the second application server now is the coordinator of the group, a connection is established to the billing system, via the terminal server, by the second application server.

    Abstract translation: 确定一组N个应用服务器的第一应用服务器是否为该组的协调器，N至少为两个。 响应于确定第一应用服务器是该组的协调器，通过终端服务器由第一应用服务器建立与计费系统的连接。 确定N个应用服务器组的第二应用服务器是否是该组的协调器。 响应于确定第二应用服务器不是组的协调器，定期检查N个应用服务器组中的第二应用服务器是否是该组的协调器。 当第一服务器遇到困难时，可以将第二应用服务器确定为该组的协调器。 一旦确定第二应用服务器现在是组的协调器，则通过第二应用服务器经由终端服务器向计费系统建立连接。

    Isoflavonoid Dimers
    34.
    发明申请
    Isoflavonoid Dimers 失效
    异黄酮二聚体

    公开(公告)号：US20080306140A1

    公开(公告)日：2008-12-11

    申请号：US11909538

    申请日：2006-03-24

    Applicant: Andrew Heaton ,  Naresh Kumar

    Inventor： Andrew Heaton ,  Naresh Kumar

    IPC: A61K31/352 ,  C07D311/78 ,  C12N5/00 ,  A61P35/00 ,  A61P29/00 ,  A61P9/00

    CPC classification number: C07D493/04

    Abstract: Novel compounds based on phenyl-substituted naphtho[1,2-g]chrysene compounds (A) are described. The compounds are obtainable by dimerisation of 3-phenylchroman (isoflavonoid) ring systems (B). Methods of synthesis of the novel dimeric compounds, compositions containing same and use of the dimers as therapeutic agents are also described.

    Abstract translation: 描述了基于苯基取代萘并[1,2-g]化合物（A）的新型化合物。 该化合物可通过3-苯基苯并二氢吡喃（异黄酮）环体系（B）的二聚得到。 还描述了新型二聚化合物的合成方法，含有它们的组合物和二聚体作为治疗剂的用途。

    Production of Furanones
    35.
    发明申请
    Production of Furanones 审中-公开
    呋喃酮的生产

    公开(公告)号：US20080167373A1

    公开(公告)日：2008-07-10

    申请号：US12051392

    申请日：2008-03-19

    Applicant: Roger Read ,  Naresh Kumar

    Inventor： Roger Read ,  Naresh Kumar

    IPC: A01N43/08 ,  C07D307/26 ,  A01P1/00 ,  C08G59/00

    CPC classification number: C08F20/00 ,  A01N43/08 ,  C07D307/58 ,  C08F24/00

    Abstract: The present invention relates to the side chain functionalization of fimbrolides (halogenated 3-alkyl-5-methylene-2(5H)-furanones) and their synthetic analogues, that yields fimbrolides substituted with a halogen, an oxygen or a nitrogen functionality in the alkyl chain, especially fimbrolide alcohols, caboxylate and sulfinate and sulfonate esters, ethers, aldehydes, ketones, acids, amides, nitro derivatives, hydrophobic, hydrophilic and fluorophilic alkyl derivatives and polymers.

    Abstract translation: 本发明涉及福滨龙（卤代3-烷基-5-亚甲基-2（5 H） - 呋喃酮）及其合成类似物的侧链官能化，其产生在卤素，氧或氮官能团中被取代的菲莫拉林 烷基链，特别是曲芬洛尔醇，卡波西铵和亚磺酸盐和磺酸酯，醚，醛，酮，酸，酰胺，硝基衍生物，疏水性，亲水性和氟性烷基衍生物和聚合物。

    Production of isoflavone derivatives
    39.
    发明申请
    Production of isoflavone derivatives 失效
    异黄酮衍生物的生产

    公开(公告)号：US20060217564A1

    公开(公告)日：2006-09-28

    申请号：US11442369

    申请日：2006-05-25

    Applicant: Andrew Heaton ,  Naresh Kumar

    Inventor： Andrew Heaton ,  Naresh Kumar

    IPC: C07D311/02

    CPC classification number: C07D311/56 ,  C07D311/36 ,  C07D311/38

    Abstract: Methods for the hydrogenation of isoflavones are described which provide access to workable quantities of isoflavan-4-ols, isoflav-3-enes, and isoflavans. The isoflavone derivatives can be obtained in high purity and in near quantitative yields whilst employing pharmaceutically acceptable reagents and solvents.

    Abstract translation: 描述了异黄酮氢化方法，其提供了可使用量的异黄烷-4-醇，异氟烷-3-烯和异构体。 异黄酮衍生物可以以高纯度和接近定量的产率获得，同时使用药学上可接受的试剂和溶剂。

Patent Agency Ranking